GlaxoSmithKline plc has updated investors and financial analysts on the Company’s broad and expanding vaccines research pipeline, which is delivering innovative products for protection against a wide range of diseases.

GSK expects to launch five major new vaccines within the next five years—
Cervarix for the prevention of HPV which causes cervical cancer; Rotarix for rotavirus gastroenteritis; Streptorix for pneumococcal disease; an improved vaccine for influenza; vaccine combinations against meningitis.

These five products will enter markets that have the potential to reach a total market value of £6-10 billion ($11-18 billion) by 2010. GSK expects each of the products to be strongly competitive and capture significant market share.

GSK estimates that cumulatively, up to 80 million women could be vaccinated by 2010 for protection against cervical cancer. Cervarix is expected to make a major contribution to this effort to improve the health of women worldwide.

GSK highlighted new clinical data at the R&D Seminar on Streptorix, on its combination meningitis vaccines, and on its improved vaccine to protect against influenza.

The launch of GSK's new paediatric vaccines, combined with its existing portfolio, will give GSK a full range of products to meet all infant vaccination schedules in all major marketswithin the first six months of life.

“The global vaccines market is poised for accelerated growth due to product innovations and a growing appreciation of the benefits of prevention over treatment,” David Stout, President of Pharmaceuticals for GSK said adding, “With over 20 vaccines in clinical development and five major launches expected in the next five years, GSK’s vaccines business is set for rapid growth, and will be a major contributor both to the Company’s overall success and to improved health across the globe.”